|
|
 | | | |
- close
- close
- close
- close
| |||||||||
Medicines Company 8-K 2010 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2010
The Medicines Company
Registrant’s telephone number, including area code: (973) 290-6000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 2.05. Costs Associated with Exit or Disposal Activities.
On February 9, 2010, The Medicines Company (the “Company”) commenced implementation of a workforce
reduction in its field-based functions to improve efficiencies and better align the Company’s costs
and structure for the future. The workforce reduction will result in the Company reducing its
personnel by 43 employees, representing approximately 26% of the Company’s field-based workforce.
Affected employees will be eligible to receive severance payments, earned 2009 bonuses, fully paid
health care coverage for six months and outplacement services. The Company expects to complete the
workforce reduction by the end of February 2010.
The Company expects to record a one-time charge of approximately $3.5 million associated with the
employee severance arrangements, which will be recognized in the first quarter of 2010.
Substantially all of this charge is expected to represent cash expenditures. The Company expects to
realize estimated annualized cost savings from the workforce reduction in the range of $8 million
to $9 million starting in the first quarter of 2010.
Forward Looking Statements
This current report includes forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. For this purpose, any statements contained herein
regarding the Company’s strategy, future operations, prospects, plans and objectives of management,
other than statements of historical facts, are forward-looking statements. The words “anticipates,”
“believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and
similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. The Company cannot guarantee that it
actually will achieve the results, plans, intentions or expectations expressed or implied in the
Company’s forward-looking statements. There are a number of important factors that could cause
actual results, levels of activity, performance or events to differ materially from those expressed
or implied in the forward-looking statements the Company makes. These important factors include the
factors set forth in the Company’s Quarterly Report on Form 10-Q filed on November 9, 2009, which
are incorporated herein by reference. The Company specifically disclaims any obligation to update
these forward looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
